KSQ Therapeutics sells early-stage targeted therapies to Japan's Ono
As it moves deeper into a Phase I trial of its lead program, KSQ Therapeutics is selling a slate of earlier-stage oncology programs in exchange for some cash.
Japan’s Ono Pharmaceutical is paying a “double-digit million upfront” to secure multiple research-stage drugs designed to attack cancer by targeting DNA damage response pathways. KSQ identified those programs — all with first-in-class potential, according to the companies — using its CRISPR screening platform.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.